COLLIRIO ALFA ® is a drug based on Naphazoline
THERAPEUTIC GROUP: Ophthalmologicals - Decongestants and antiallergics
Indications EYE DROPS ALFA ® Nafazoline
COLLIRIO ALFA ® is indicated in the topical treatment of irritation of the eye characterized by burning, redness, itching and tearing.
Mechanism of action EYE DROPS ALFA ® Nafazoline
COLLIRIO ALFA ® owes its therapeutic activity to the presence of its active ingredient Nafazolin.
In fact, naphazoline is a sympathomimetic drug capable of binding alpha1 and alpha2 adrenergic receptors at the level of vascular smooth muscle, reducing the turgor of the inflamed ocular mucosa associated with the oedematous condition caused by vascular overflow.
This mechanism of action allows in a very limited time to significantly improve the patient's clinical conditions, keeping this condition active for a few hours.
Studies carried out and clinical efficacy
NAFAZOLINE IN THE TREATMENT OF MYOPATHIC PTOSIS
Acta Neurol Scand. 1993 Apr; 87: 322-4.
Topical naphazoline in treatment of myopathic ptosis.
Uncini A, De Nicola G, Di Muzio A, Rancitelli G, Colangelo L, Gambi D, Gallenga PE.
Italian study that demonstrates how naphazoline can guarantee an improvement of myopathic eyelid ptosis, probably by acting on the alpha two receptors of the levator muscle of the upper eyelid, without however side effects worthy of clinical note.
NAFAZOLINE AND REDUCTION OF ENDOCULAR PRESSURE
Exp Eye Res. 2001 Mar; 72: 331-9.
Naphazoline-induced suppression of aqueous humor pressure and flow: involvement of central and peripheral alpha / I receptors.
Ogidigben MJ, Chu TC, Potter DE.
Study that demonstrates how naphazoline can suppress the production of aqueous humor, causing a sensitive ocular hypotensive effect, probably also associated with an inhibitory action against central alpha-adrenergic receptors.
NAPHAZOLINE POISONING
Forensic Sci Int. 2003 Jul 8; 134 (2-3): 234-7.
Naphazoline intoxication in a child-a clinical and forensic toxicological case.
Musshoff F, Gerschlauer A, Madea B
Clinical case reporting naphazoline intoxication in a small 6-year-old patient treated with a galenic drug prepared with naphazoline concentrations 80 times higher than normal.
Method of use and dosage
EYE DROPS ALFA ®
Eye drops of 0.8 mg of Naphazoline nitrate per ml of solution.
It is generally recommended to instill 1-2 drops of eye drops directly into the conjunctival sac once or twice a day for a maximum of 4 consecutive days.
In the event that there is no improvement in symptoms, it would be advisable to consult your doctor and consider the possibility of changing therapy.
Warnings EYE DROPS ALFA ® Nafazoline
Although the systemic absorption of naphazoline used by topical ocular route is not relevant, it is advisable that patients suffering from hypertension, heart disease, asthma, hyperglycemia and hyperthyroidism pay particular attention to the use of COLLIRIO ALFA ®, periodically consulting their doctor.
It is also recommended not to exceed the indicated treatment periods, in order to avoid the appearance of unpleasant local side effects.
The presence in COLLIRIO ALFA ® of benzalkonium chloride could be problematic for patients with contact lenses or for patients hypersensitive to this excipient.
PREGNANCY AND BREASTFEEDING
The use of COLLIRIO ALFA ® during pregnancy and in the subsequent period of breastfeeding should be limited to cases of real need, and always take place under the strict supervision of your doctor.
Interactions
No drug interactions worthy of clinical note are currently known.
Contraindications EYE DROPS ALFA ® Nafazoline
The patient in therapy with antidepressant drugs, and in particular with monoamine oxidase inhibitors, should avoid the simultaneous use of COLLIRIO ALFA ® for potential hypertensive side effects.
Undesirable Effects - Side Effects
The use of COLLIRIO ALFA ®, especially if prolonged over time, could cause the appearance of local side effects such as increased intraocular pressure, nausea, headache and hypersensitivity reactions.
Fortunately, systemic side effects are rarer.
Note
COLLIRIO ALFA ® is a drug not subject to mandatory medical prescription.
The information on COLLIRIO ALFA ® Nafazolina published on this page may be out of date or incomplete. For a correct use of this information, see the Disclaimer and useful information page.